Tag: pharmaceutical industry

A new round of Medicare drug price negotiations shows the impact of the Inflation Reduction Act while exposing an ongoing political fight over who deserves credit for lowering drug costs.

Senate parliamentarian reverses an earlier ruling, letting a provision that shields multi-use orphan drugs from Medicare price talks ride on Republicans’ budget package as patient advocates warn of higher costs for taxpayers and seniors.

The president’s directive to lower prescription costs relies on voluntary compliance and vague rulemaking powers, leaving analysts and advocates questioning its efficacy.

Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue.

Endo “came with a strategy purposely intended to reduce payments to opioid victims."

The suit also includes their affiliated group purchasing organizations (GPOs), accusing them of blocking patients from accessing cheaper alternatives and distorting drug markets for profit.

As Novo Nordisk rakes in billions, Sen. Bernie Sanders and public health advocates demand answers on why U.S. patients are charged sky-high prices for life-saving drugs like Ozempic while generics could sell for a fraction of the cost.

A Maine woman’s story highlights the impact of progressive action on drug prices.

President Biden and Sen. Bernie Sanders call out pharmaceutical companies for overcharging Americans, urging immediate reform.

The Federal Trade Commission intensifies its fight against pharmaceutical patent abuses, aiming to slash drug prices and increase access to generic medications.